Partners
Novocure
Expertise Partner
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, TTFields. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
FYR
Innovation Partner
FYR is a pioneering liquid biopsy company focused on unlocking the power of the multi-omic content of Extracellular Vesicles (EVs) for detection, profiling, and monitoring of disease. FYR leverages proprietary enrichment technology, called SPARCs, to isolate tumor derived EVs from the blood, enabling the enhanced collection and analysis of disease-associated multi-omic data. Utilizing this platform, FYR is developing novel solutions for multiple applications in neuro-oncology, including diagnostics, treatment selection, and longitudinal disease monitoring.
End Brain Cancer
Exhibition Partner
The End Brain Cancer Initiative (EBCI), formerly the Chris Elliott Fund,www.EndBrainCancer.org, is a 501 (c)3 non-profit Patient Advocacy organization focused on early drug development and increasing patient and care partner access to advanced treatments, diagnostics, devices, technology, clinical trials, etc. and on advancing and turning science and data into additional FDA approved treatment options for cancer patients, including brain tumors, brain cancer and metastasized disease to the brain and again, increasing patient access through commercialization and reimbursement efforts. Specifically, we partner with industry/sponsors to accomplish these goals by:
- Offering our 22+ years of expertise to assist sponsors in early drug development and improving patient access to diagnostics, devices, clinical trials, etc. by developing surveys/questionnaires, patient disease education ads/flyers, clinical trial protocol, etc. by “inserting the patient and care partner voice” into all aspects of development.
- EBCI creates strategic patient disease education, awareness & outreach campaigns focused on the above and recruits for the above projects on a project by project basis
- EBCI develops, produces, manages and MC’s patient/care partner focus groups/roundtables.
- EBCI provides opportunities for industry/sponsors, researchers, specialists, etc. to share their product, drug, device, diagnostic, etc. directly with the general public and to patients, care partners, families and specific communities via online platforms, websites, our disease mobile application, Initiative Sponsorships, Corporate Partnership Sponsorships, Disease Education Program Grants, Consulting Services, etc.
To partner to increase patient access, please contact, President, CEO and Chair, Dellann Elliott Mydland, directly at Dellann@EndBrainCancer.org or at 425-785-8489.
Kiyatec
Exhibition Partner
Kiyatec is a functional precision oncology company that accurately measures
the response of each patient’s live cancer cells to aid in drug development
and inform clinical treatment decisions. The company works in partnership
with leading biopharmaceutical companies to unlock response dynamics
for their pre-clinical investigational drug candidates across most solid tumor
types. Kiyatec’s CLIA- certified labs offer clinical testing for high-grade
glioma, and is developing assays for use in ovarian, breast, NSCLC, and rare
tumors.
Renishaw
Exhibition Partner
Renishaw Neuro Solutions enables direct-to-target delivery for a broad range of applications. Using the neuroinfuse™ drug delivery system, predictable and translatable therapy infusions in R&D and clinical trials can become a reality. Our Lab2Clinic™ service supports pharma through the R&D journey, translating into clinical trials and scaled-up commercialisation. We have a wide geographical reach, and we focus on promoting long-term partnerships. All this is underpinned by our FDA-cleared, CE-marked stereotatic products borne out of a +45-year precision engineering heritage.
Sutter Health
Exhibition Partner
The Cancer Avatar Program at the CPMC Research Institute, part of the
Sutter Health network, has collected hundreds of samples from eight
common cancers (brain, colorectal, lung, melanoma, ovarian, pancreatic,
breast, and liver/biliary) to develop a comprehensive biobank. Leading
the way for cancer precision medicine research in Northern California, our
scientists work with oncologists and surgeons to create cell culture and
mouse models, or “avatars” of patients’ tumors.